All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation
During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma? Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US, answered: Is transplantation still relevant? If yes, in which context?
Welcome to the Multiple Myeloma Hub Satellite Symposium.
Please take a moment to complete the survey and answer the following question to help us gauge your current understanding of the treatment of multiple myeloma.
In this presentation, Lonial describes results from the FORTE (NCT02203643) and IFM 2009 (NCT01191060) trials, which investigated the use of triplet combinations with and without transplant. He warns of the 'siren song' of early MRD negativity that may lead one to believe novel agents are just as good as transplant. Lonial highlights that the focus needs to be on sustained MRD negativity; rates of which were higher in the patients who received a transplant. He also highlights two reasons for the discrepancy seen among early MRD negativity and sustained MRD negativity between patients who received a transplant and those who did not.
Is transplantation still relevant? If yes, in which context? Sagar Lonial
Sagar Lonial's slides are available as a downloadable resource below.Download the slides here!
Find below links to the other talks from the symposium:
'Does 'cure' have a different meaning in MM?' presented by Mohamad Mohty.
'Is the treatment of high-risk smoldering multiple myeloma (SMM) the way for achieving the cure?' presented by María-Victoria Mateos.
'Treating elderly and frail patients with MM: Cure versus disease control' presented by Vincent Rajkumar.
'Roundtable discussion' with María-Victoria Mateos, Mohamad Mohty, and Sagar Lonial.
Educational theme: Measurable residual disease (MRD)
This month’s educational theme on the Multiple Myeloma (MM) Hub is centered around measurable residual disease (MRD; also referred to as minimal residual disease).
ASCO 2019 | Risk subgroup analysis from the FORTE trial
On Sunday 02 June, 2019, Francesca Gay, University of Torino, Torino, IT, presented an updated risk analysis from the FORTE trial (NCT02203643) during the ASCO meeting.
Subscribe to get the best content related to multiple myeloma delivered to your inbox